Safety/Efficacy Study of SGN-15 (Antibody-Drug Conjugate) Combined With Gemcitabine in Patients With Ovarian Cancer

Brief Overview of Inclusion Criteria: * Patients must have pathologically confirmed ovarian cancer, which is advanced or recurrent carcinoma, who have failed at least two, but no more than three prior therapies for metastatic disease * Patients must have \> 20% Lewis-y antigen expression documented by immunohistochemistry * LVEF \> 50% by echo or MUGA * Must be platinum resistant as defined by: * Progression while on initial platinum therapy or * Progression while on retreatment with initial platinum regimen or * Relapse \< 6 months after initial therapy Brief Overview of Exclusion Criteria: * Patients who have had prior therapy with Gemzar® * Cumulative anthracycline exposure \> 300 mg/m2 * More than three prior chemotherapy regimens for ovarian cancer (Retreatment with Taxane/Platinum after initial combination is considered only one regimen)